Evidence map›Paper›PMID 31919934›Full record

ArticleEuropean journal of heart failure2020

Genetic risk and atrial fibrillation in patients with heart failure.

Mariëlle Kloosterman, Bernadet T Santema, Carolina Roselli, Christopher P Nelson, Andrea Koekemoer, Simon P R Romaine, Isabelle C Van Gelder, Carolyn S P Lam, Vicente A Artola, Chim C Lang and 13 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Understanding the Diseased Atria.Physiology (Bethesda, Md.) · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 9 countries.

Mariëlle KloostermanDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Bernadet T SantemaDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Carolina RoselliDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Christopher P NelsonDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK.
Andrea KoekemoerDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK.
Simon P R RomaineDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK.
Isabelle C Van GelderDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Carolyn S P LamDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Vicente A ArtolaDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Chim C LangSchool of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.
Leon L NgDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK.
Marco MetraInstitute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Stefan AnkerDepartment of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Berlin, Germany.
Gerasimos FilippatosAthens University Hospital, Athens, Greece.
Kenneth DicksteinUniversity of Bergen, Stavanger University Hospital, Bergen, Norway.
Piotr PonikowskiDepartment for Heart Disease, Centre for Heart Disease, University Hospital, Medical University, Wroclaw, Poland.
Pim van der HarstDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Peter van der MeerDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Dirk J van VeldhuisenDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Emelia J BenjaminDepartment of Medicine, Boston University School of Medicine, Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
Adriaan A VoorsDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Nilesh J SamaniDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK.
Michiel RienstraDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
University Medical Center Groningen · NLUniversity of Groningen · NLUniversity of Leicester · GBNIHR Leicester Biomedical Research Centre · GBAthens State University · USBerlin-Brandenburger Centrum für Regenerative Therapien · DEBoston University · USBroad Institute · USNational Heart Centre Singapore · SGNinewells Hospital · GBSurgical Specialties (Canada) · CAUniversity of Bergen · NOWroclaw Medical University · PL

Funding

British Heart FoundationDutch Heart FoundationEuropean Commission
6 · The paper itself

Abstract

aimsTo study the association between an atrial fibrillation (AF) genetic risk score with prevalent AF and all-cause mortality in patients with heart failure. METHODS AND

resultsAn AF genetic risk score was calculated in 3759 European ancestry individuals (1783 with sinus rhythm, 1976 with AF) from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) by summing 97 single nucleotide polymorphism (SNP) alleles (ranging from 0-2) weighted by the natural logarithm of the relative SNP risk from the latest AF genome-wide association study. Further, we assessed AF risk variance explained by additive SNP variation, and performance of clinical or genetic risk factors, and the combination in classifying AF prevalence. AF was classified as AF or atrial flutter (AFL) at baseline electrocardiogram and/or a history of AF or AFL. The genetic risk score was associated with AF after multivariable adjustment. Odds ratio for AF prevalence per 1-unit increase genetic risk score was 2.12 (95% confidence interval 1.84-2.45, P = 2.15 × 10

conclusionsThe AF genetic risk score was associated with increased AF prevalence in HFrEF and HFpEF. Genetic variation accounted for 22.9% of overall AF SNP heritability. Addition of genetic risk to clinical risk improved model performance in classifying AF prevalence.

Indexed as

Atrial FibrillationHeart FailureAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsFemaleGenome-Wide Association StudyHumansMiddle AgedPrognosisRisk FactorsStroke VolumeVentricular Function, LeftAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAtrial fibrillationGenetic association studiesHeart failureRisk factorsSingle nucleotide polymorphism

Identifiers

PMID31919934
PMCPMC7319410
OpenAlexW2999063445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.